Advertisement
Articles
Advertisement

Focus on Clinical 10/13/06

Fri, 10/13/2006 - 8:24am
Crucell and NIH VRC Announce Start of Ebola Vaccine Clinical Trial
Crucell N.V., Leiden, The Netherlands, today announced that the Ebola vaccine it is developing in partnership with the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases, part of the US National Institutes of Health (NIH), has commenced its randomized, double-blind, placebo-controlled, phase I clinical study, which will test the single-shot vaccination in a dose-escalation trial.
Full Article

Trubion Initiates Phase IIb Trial of TRU-015 to Treat Rheumatoid Arthritis
Trubion Pharmaceuticals Inc., Seattle, has initiated a phase IIb randomized, double-blind, placebo-controlled, clinical trial of TRU-015, its lead small modular immunopharmaceutical drug candidate to treat rheumatoid arthritis.
Full Article

QuatRx Initiates Phase I Trial to Reduce LDL Cholesterol and Lipoprotein (A)
QuatRx Pharmaceuticals, Ann Arbor, Mich., a privately held biopharmaceutical company, initiated a phase I clinical study of QRX-431, a selective thyroid beta agonist, in development to treat elevated cholesterol levels and obesity.
Full Article

Astex Therapeutics Initiates Clinical Trial with Anti-Cancer Drug
Astex Therapeutics, Cambridge, UK, has begun dosing first patients in a phase I/IIa clinical trial of its investigational anti-cancer drug AT9283, a potent inhibitor of Aurora kinases, and plans to initiate additional clinical studies of AT9283 in North America and Europe within the next six months.
Full Article

EntreMed Commences MKC-1 Clinical Trial in Leukemia Patients
EntreMed Inc., Rockville, Md., commenced a phase I study with its clinical-stage drug candidate, MKC-1, in patients with hematological (blood) malignancies. MKC-1 is also being evaluated currently in a phase II clinical study in patients with metastatic breast cancer.
Full Article

Alba Therapeutics Announces Phase II Trial for Zonulin Antagonist AT-1001
Alba Therapeutics Corp., Baltimore, Md., dosed its first patient using AT-1001, an orally administered zonulin receptor antagonist, in a multi-center, double blind, placebo controlled dose ranging, phase II trial to treat celiac disease.
Full Article

BioMarin Completes Enrollment of Phase II Study of 6R-BH4 in Hypertension
BioMarin Pharmaceutical Inc., Novato, Calif., completed enrollment of a multicenter, double-blind, placebo-controlled, phase II clinical study of 6R-BH4 to treat poorly controlled hypertension.
Full Article

Sanofi pasteur Begins First Clinical Trial of Novel Cell-Based H7N1 Vaccine
Sanofi pasteur, Lyon, France, the vaccines business of the sanofi-aventis Group, has generated the first clinical trial lot of a new generation of H7N1 pandemic vaccine, which will broaden its pandemic preparedness program initiated with the development of H5N1 vaccines.
Full Article

Rigel Launches Phase I Study Evaluating R763 in Solid Tumors
Rigel Pharmaceuticals Inc., South San Francisco, announced that its partner Serono has begun enrolling patients in a phase I study evaluating the safety and tolerability of R763, a highly potent, orally available multi-Aurora kinase inhibitor, to treat patients with refractory solid tumors.
Full Article

Pharmion Initiates Phase II Trial with HDAC Inhibitor in Lymphoma
Pharmion Corp., Boulder, Colo., announced, along with its partner MethylGene Inc. the initiation of a phase II clinical trial with its lead histone deacetylase (HDAC) inhibitor product candidate, MGCD0103, in patients with relapsed or refractory B-cell lymphomas.
Full Article


Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading